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Abstract
Background: Early diagnostic and prognostic stratification of patients with suspected infection is a difficult clinical
challenge. We studied plasma pentraxin 3 (PTX3) upon admission to the emergency department in patients with suspected
infection.
Methods: The study comprised 537 emergency room patients with suspected infection: 59 with no systemic inflammatory
response syndrome (SIRS) and without bacterial infection (group 1), 67 with bacterial infection without SIRS (group 2), 54
with SIRS without bacterial infection (group 3), 308 with sepsis (SIRS and bacterial infection) without organ failure (group 4)
and 49 with severe sepsis (group 5). Plasma PTX3 was measured on admission using a commercial solid-phase enzyme-
linked immunosorbent assay (ELISA).
Results: The median PTX3 levels in groups 1–5 were 2.6 ng/ml, 4.4 ng/ml, 5.0 ng/ml, 6.1 ng/ml and 16.7 ng/ml, respectively
(p,0.001). The median PTX3 concentration was higher in severe sepsis patients compared to others (16.7 vs. 4.9 ng/ml,
p,0.001) and in non-survivors (day 28 case fatality) compared to survivors (14.1 vs. 5.1 ng/ml, p,0.001). A high PTX3 level
predicted the need for ICU stay (p,0.001) and hypotension (p,0.001). AUCROC in the prediction of severe sepsis was 0.73
(95% CI 0.66–0.81, p,0.001) and 0.69 in case fatality (95% CI 0.58–0.79, p,0.001). PTX3 at a cut-off level for 14.1 ng/ml
(optimal cut-off value for severe sepsis) showed 63% sensitivity and 80% specificity. At a cut-off level 7.7 ng/ml (optimal cut-
off value for case fatality) showed 70% sensitivity and 63% specificity in predicting case fatality on day 28.In multivariate
models, high PTX3 remained an independent predictor of severe sepsis and case fatality after adjusting for potential
confounders.
Conclusions: A high PTX3 level on hospital admission predicts severe sepsis and case fatality in patients with suspected
infection.
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Introduction
Severe sepsis is a important disease associated with significant
mortality [1]. Early diagnosis and stratification of sepsis patients
is difficult but essential, because early interventions and
appropriate antimicrobial treatment can be life saving [2,3].
Biomarkers could play an important role in this process if they
can indicate sepsis or its severity [4,5]. C-reactive protein
(CRP), the prototype of short pentraxin, has been widely used,
but its specificity as a diagnostic tool is limited [6,7], and it is
also a poor prognostic marker [8]. Procalcitonin (PCT) has been
proposed as a more specific etiologic and prognostic mar-
ker than CRP [9,10], although its value has also been
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challenged [11]. The search for better biomarkers of sepsis thus
continues.
Pentraxin 3 (PTX3) is the prototype of the long pentraxin family
[12,13]. It differs from CRP in terms of gene organization and
localization, ligand recognition, producing cells and inducing
signals [14,15,16]. CRP is produced in the liver, whereas PTX3 is
an inflammatory mediator produced by various cells in peripheral
tissues. PTX3 is an acute-phase protein whose plasma concentra-
tions increases rapidly in various inflammatory conditions,
including sepsis [17]. It plays an important role in the early phase
of inflammation: it recognizes microbial moieties, activates the
classical pathway of complement and facilitates recognition by
macrophages and dendritic cells [18]. PTX3 has an important role
in regulating the innate immune response by contributing to the
opsonization and clearance of apoptotic or necrotic cells [19].
In one previous study a high PTX3 has been shown to predict
sepsis and severe disease in febrile patients admitted to emergency
department [20]. In critically ill patients PTX3 correlated with
severity of disease and infection [21]. High PTX3 has been shown
to be associated with mortality in severe sepsis [22] and bacteremic
patients [23]. High PTX3 has also been found to be an early
indicator of shock in severe meningococcal disease [24].
Aim of the present study was to evaluate the usefulness of
plasma PTX3 determination in early stratification and in
predicting the development of severe sepsis and mortality in a
large and unselected cohort of patients with suspected infection
admitted to the emergency room. PTX3 results are compared to
CRP and PCT levels. We found that a high PTX3 concentration
predicted severe disease and poor outcome in this cohort.
Methods
Patients
The aim here was to evaluate early prognostic and etiologic
utility of PTX3 in patients with suspected infection in an
emergency room setting. The same cohort of patients has
previously been involved in three published studies [25,26,27].
Patients were recruited in Satakunta Central Hospital, a 350-bed
secondary care hospital in Western Finland serving the Satakunta
Hospital District with a population of 240 000 inhabitants. It is the
only hospital in the area with an emergency department and an
intensive care unit. The study was approved by the ethical review
board of the Satakunta Hospital District. Written consent was
obtained from patients or close relatives.
The study cohort comprised adult patients admitted to the
emergency room with suspected infection, from whom a clinician
had decided to take samples for blood cultures. Enrolment took
place over a 14-month period in 2004 to 2005. To ensure written
informed consent and interview within 24–48 hours, only patients
admitted between Sunday 7 a.m. and Wednesday 3 p.m. were
enrolled. Prior to the study, a pre-evaluation of the target
population was conducted to ensure the representativity of the
cohort. The assessment covered 1551 consecutive patients from
whom blood cultures had been taken in the emergency
department. The rate of positive findings was 8.3% and case
fatality by day 28 after admission 6.7%. No significant differences
were noted between patients in respect of study days and other
days or between the study and the pre-evaluated populations
regarding age, gender, rate of positive blood cultures or mortality.
Blood samples for the study were taken upon admission
concurrently with the blood culture samples. Blood was collected
into two 10-ml EDTA tubes (plasma) and two 7-ml serum tubes
(serum). The EDTA tubes were kept on ice until centrifugation at
room temperature using 2500 G-force 10–15 min. Plasma and
serum were transferred in 1–2-ml aliquots to CryoPureH (Sarstedt,
Germany) tubes. These were stored at 270uC until assayed.
A structured interview was undertaken by the investigator or
research nurse 24–48 hours after admission. Highest body
temperature, lowest blood pressure, highest pulse, respiratory
rates were recorded daily on days 1–7. Symptoms and clinical
signs, Glasgow coma scale, risk factors for sepsis, underlying
diseases and diagnosis at admission were recorded, likewise
duration of stay in intensive care and in hospital. Potential organ
failure on days 0–28 (respiratory, cardiovascular, renal, hemato-
logical, hepatic or central nervous system), overall case fatality (day
28) and sepsis-attributable case fatality were recorded. Final
diagnoses, source of infection and trauma or other possible reasons
for inflammation were taken from medical reports. A follow-up
check was made by phone 3 months and one year after enrolment.
Blood samples for the study were taken from 609 patients. Fifty-
five patients (or close relatives) refused to participate, and their
blood samples were destroyed. Fifteen were excluded from the
analysis: one due to a missing blood sample at admission, 11 due to
incomplete data for classification as to whether they had bacterial
infection or not, and three who had SIRS and organ dysfunction
but no bacterial infection (one with epidemic nephropathy and
Table 1. Demographics of study population (N= 537).
Characteristics
Age, median (range) 64 (18–100)
Gender (female/male) 227/310
Obesity (BMI$30)a 119 (30.5%)
Alcohol abuseb 25 (4.7%)
Smoking (current smoker) 126 (23.5%)
Diabetes (type 1 and 2) 81 (15.1%)
Malignancy (solid or haematological) 95 (17.7%)
Rheumatic diseases 50 (9.3%)
Chronic renal insufficiencyc 18 (3.4%)
Cardiovascular diseased 289 (53.8%)
COPD or asthmae 108 (20.1%)
Operation six months previously 75 (14.0%)
Devicef 82 (15.3%)
Continuous medicationg 389 (72.4%)
Continuous cortisone treatmenth 59 (11.0%)
Blood culturesi
Positive (clinically significant) 47 (8.8%)
Positive (contamination) 4 (0.7%)
Blood cultures taken after antimicrobial
treatment has started
136 (25.4%)
abody mass index. Data available on 390 patients.
balcoholism was diagnosed or patient had previously been treated for alcohol-
induced disease.
cplasma creatinine concentration constantly more than 170 mmol/l (5 patients
had chronic dialysis treatment).
dcontinuous medication for cardiovascular disease (i.e. hypertension,
arteriosclerosis or other cardiovascular disease).
econtinuous medication for asthma or COPD.
fjoint or heart valve prosthesis or pace-maker (does not include dental
implants).
gcontinuous medication for a chronic disease.
hcontinuous systemic cortisone treatment (daily dose more than 10 mg of oral
prednisolone).
iBlood cultures were taken from 536 patients.
doi:10.1371/journal.pone.0053661.t001
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two with myocardial infarction). Two patients were excluded as
their plasma samples had run out. The final study material thus
comprised of 537 patients.
Laboratory Methods
The PTX3 concentration in EDTA plasma was determined
using a commercial solid-phase enzyme-linked immunosorbent
assay (ELISA) (QuantikineH DPTX 30; R&D Systems Inc.,
Minneapolis, USA). The level of procalcitonin (PCT) in plasma
was measured by immunochemiluminometric assay (ECLIA) in a
Modular E170 automatic analyzer (Roche Diagnostics GmbH,
Mannheim, Germany), and the level of C-reactive protein (CRP)
in plasma by an immunoturbidimetric assay using a Modular P800
automatic analyzer (Roche Diagnostics GmbH).
Statistical Analysis
An SPSS package (version 15) was used for statistical analyses
and a two-sided p-value ,0.05 was taken as cut-off for statistical
significance. Categorical data were analyzed by X2 test or Fishers
exact test when appropriate, and nonparametric continuous data
by Mann-Whitney U-test or Kruskal-Wallis test. SAS (version 9.2)
was used for logistic regression analysis. A logistic regression
model, adjusted for potential confounders, was used to study the
independent effect of high PTX3 activity on mortality and severe
sepsis. Odds ratios (ORs) were expressed with their 95%
confidence intervals (CI) when appropriate. The accuracy of a
high PTX3 value in predicting severe sepsis and case fatality was
assessed using ROC curves [28]. In this method, a test which is
perfect has 100% sensitivity and no false positives (1-specificity = 0)
and will have an area under the curve (AUC) of 1.0, whereas a test
of no diagnostic value would have an AUC of 0.5. The 95%
confidence intervals were calculated. The Youden index with the
highest sum of sensitivity and specificity was used to select the
optimal cut-off for analysis. Correlations between PTX3, CRP and
PCT were analyzed using Spearman’s rank analysis.
Results
Demographic data on the study population are shown in
Table 1. Table 2 gives the distribution of the cohort into five study
groups on the basis of ACCP/SCCM Consensus Conference
definitions [29]. The median PTX3 level in all patients was 5.4
(range 0.3–514 ng/ml).
PTX3 values showed a positive correlation with PCT (r = 0.562,
p,0.001) and CRP (r = 0.222, p,0.001), WBC (r = 0.236,
p,0.001) and creatinine concentration (r = 0.171, p,0.001). A
weak negative correlation was documented with platelet count
(r =20.209, p,0.001).
Plasma PTX3 values stratified by demographics, underlying
conditions and clinical data are presented in Table 3. The median
PTX3 was significantly higher in patients with severe sepsis as
compared to others (16.7 vs. 4.9 ng/ml, p,0.001) and in non-
survivors (day 28 case fatality) as compared to survivors (14.1 vs.
5.1 ng/ml, p,0.001).
The optimal cut-offs for PTX3, PCT and CRP in predicting
severe sepsis between day 0 and day 28 and case fatality were
estimated using ROC curves (Figure 1) and Youdens index.
AUCROC for prediction of severe sepsis was 0.73 (95% CI
0.66–0.81, p,0.001) for PTX3. The AUC value for PCT was
0.77 (95% CI 0.71–0.84, p,0.001) and 0.60 for CRP (95% CI
0.51–0.69, p = 0.027). The optimal cut-off value for PTX3 in
predicting severe sepsis was 14.1 ng/ml (specificity 80% and
sensitivity 63%), for PCT 0.30 ng/ml (specificity 66% and
sensitivity 82%) and for CRP 158 mg/l (specificity 70% and
sensitivity 47%).
In predicting case fatality on day 28, AUCROC was 0.69 (95%
CI 0.58–0.79, p,0.001) for PTX3, 0.65 (95% CI 0.57–0.74,
p = 0.003) for PCT and 0.50 (95% CI 0.38–0.62, p = 0.966) for
CRP. A PTX3 level of 7.7 ng/ml showed a sensitivity of 70% and
specificity of 63% in predicting case fatality on day 28. For PCT
the optimal cut-off level was 0.19 ng/ml (sensitivity 82% and
Table 2. Plasma pentraxin 3 (PTX3) in patients admitted to emergency room with suspected infection stratified by diagnosis
groups (N = 537).
Diagnosis group Criteria
Pentraxin 3 (ng/ml)
median (quartiles)
1. No SIRS, no bacterial infection (N = 59) Patients with no SIRSa (less than two SIRS criteria at
admission +/224 hours), nor documentedb or
probable c bacterial infection
2.6 (1.4–5.8)
2. Bacterial infection, no SIRS (n = 67) Patients with documented or probable bacterial
infection, but no SIRS (less than two SIRS criteria at
admission +/224 hours)
4.4 (2.3–9.3)
3. SIRS, no bacterial infection (n = 54) Patients with SIRS (at least two SIRS criteria at
admission +/224 hours), but no documented or
probable bacterial infection
5.0 (2.3–13.2)
4. Sepsis (n = 308) Patients with sepsis (SIRS and documented or
probable bacterial infection but no organ
dysfunction due to sepsis)
6.1 (2.8–14.2)
5. Severe sepsis (n = 49) Patients with severe sepsis (sepsis with signs
of organ failure, i.e. disturbed perfusion,
metabolic acidosis, oliguria or neurological disorders)
16.7 (4.7–54.7)
aSIRS (Systemic Inflammatory Response Syndrome): At least two of the following conditions. 1. Temperature .38uC OR ,36uC, 2. Heart rate .90 beats per minute. 3.
Respiratory rate .20 breaths per minute or PaCO2,32 mmHg (4.3 kPa). 4. White blood cell count .126109/l or ,46109/l or .10% immature (band) forms).
bDocumented bacterial infection: Microbiologically confirmed bacterial infection (either pathogenic bacterial growth in blood culture or in normally sterile tissue or the
same usually less pathogenic bacterium (e.g. Staphylococcus epidermidis) in two different samples).
cProbable bacterial infection: A clinician suspected bacterial infection and either infection focus was confirmed or antimicrobial treatment was started and the response
to treatment supported bacterial infection.
Differences between the five groups were studied using Kruskal-Wallis test (p,0.001).
doi:10.1371/journal.pone.0053661.t002
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specificity 63%). PTX3 predicted death also at 1 year follow up
(table 3).
The clinical characteristics of patients stratified by PTX3 value
as registered on admission are shown in Table 4. A high PTX3
level ($14.1 ng/ml; optimal cut-off value for severe sepsis) was
associated with day 28 case fatality and several endpoints reflecting
the severity of the disease (need for ICU stay, hypotension and
acute renal insufficiency (p,0.001)).
In a univariate model high PTX3, PCT and CRP values
predicted severe sepsis when used as continuous or grouping
variables. Alcohol abuse and continuous systemic cortisone
treatment were also factors associated with severe sepsis in the
univariate mode (data not shown). Parameters expressing signif-
icant associations were then combined in the multivariate model,
first without and then with potential demographic confounders.
Results are presented in Table 5.
High PTX3, PCT, age over 60 years, alcohol abuse, diabetes
and continuous systemic cortisone treatment were associated with
case fatality (d28) in the univariate model while the level of CRP
was not (data not sown). These parameters were studied together
in the multivariate model first without and then with potential
demographic confounders. Results are shown in Table 6.
Discussion
The results presented here show that high PTX3 levels on
admission can be used to predict severe sepsis and case fatality in
patients admitted to the emergency room with suspected infection.
Table 3. Plasma pentraxin 3 (PTX3) values stratified by demographics and clinical data in patients admitted to the emergency
room with suspected infection. N = 537.
PTX3 (ng/ml) on admission. Stratification by clinical parameter p-value
Factor present Factor absent
Characteristic N median (quartiles) N median (quartiles)
Age .60 years 312 6.3 (3.0–14.3) 225 4.0 (2.0–12.7) ,0.001
Gender (male) 310 5.2 (2.6–14.1) 227 5.8 (2.6–11.9) 0.887
Obesity (BMIa $30) 119 4.4 (2.6–9.8) 271 6.5 (2.8–15.0) 0.017
Alcohol abuseb 25 12.7 (2.8–17.1) 512 5.3 (2.6–12.7) 0.088
Smoking (current smoker) 126 4.5 (2.5–15.5) 411 5.6 (2.6–13.0) 0.565
Diabetes (type 1 and 2) 81 5.8 (2.8–14.6) 456 5.3 (2.6–12.8) 0.134
Solid cancer 78 5.5 (2.9–11.4) 459 5.4 (2.6–14.1) 0.868
Malignancy 95 5.6 (2.9–11.6) 442 5.3 (2.6–14.1) 0.762
Rheumatic diseases 50 6.1 (2.8–11.4) 487 5.3 (2.6–14.0) 0.614
Chronic renal insufficiencyc 18 7.0 (4.7–15.3) 519 5.3 (2.6–13.5) 0.336
Cardiovascular diseased 289 6.4 (2.9–14.3) 248 4.5 (2.3–12.1) 0.002
Continuous cortisone treatmente 59 7.6 (4.3–15.9) 478 5.0 (2.6–13.0) 0.022
Clinical parameter (d 0–28)
Case fatality (d 28) 33 14.1 (5.2–53.6) 504 5.1 (2.6–12.5) ,0.001
Case fatality (d 90) 58 11.3 (4.5–39.7) 479 4.9 (2.6–12.2) ,0.001
Case fatality (1 year) 112 7.6 (3.8–30.8) 425 4.7 (2.5–12.2) ,0.001
ICUf stay needed 42 11.6 (4.4 - 43.6) 495 5.2 (2.5–12.2) ,0.001
Hypotensiong 28 17.8 (4.3–62.9) 509 5.3 (2.6–12.2) ,0.001
Vasopressors needed 19 14.2 (4.3–67.0) 518 5.3 (2.6–12.8) 0.015
DICh 8 46.2 (21.8–153.9) 529 5.3 (2.6–12.8) 0.001
Decreased GCSi 26 15.4 (4.6–58.2) 511 5.3 (2.6–12.6) ,0.001
Needed mechanical ventilation 14 11.6 (2.8–53.9) 523 5.4 (2.6–13.0) 0.081
Needed C-PAP/bi-PAPj 22 9.0 (3.3–28.3) 515 5.3 (2.6–13.0) 0.064
Sepsis+organ dysfunction 49 16.7 (4.7–54.7) 488 4.9 (2.5–11.7) ,0.001
MOFk 10 46.2 (9.0–215.8) 527 5.3 (2.6–13.0) 0.001
abody mass index, data available on 390 patients.
balcoholism was diagnosed or patient had previously been treated for alcohol-induced disease.
cplasma creatinine concentration constantly more than 170 mmol/l (5 patients had chronic dialysis treatment).
dcontinuous medication for cardiovascular disease (i.e. hypertension, arteriosclerosis or other cardiovascular disease).
econtinuous systemic cortisone treatment (daily dose more than 10 mg of oral prednisolone).
fIntensive care unit.
gsystolic blood pressure ,90 mmHg or a reduction of 40 mmHg from baseline. No response to 500 ml intravenous fluid replacement.
hdisseminated intravascular coagulation.
IGlasgow coma scale ,15.
jcontinuous positive airway pressure/bilevel positive airway pressure.
kmulti-organ failure.
doi:10.1371/journal.pone.0053661.t003
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Both PTX3 and PCT remained independent predictors for severe
sepsis and case fatality also after adjustment for potential
confounders whereas high CRP did not.
In healthy persons the PTX3 concentration has been shown to
be lower than 2 ng/ml, while PTX3 levels increase rapidly in
response to inflammation and infection [19,30]. A previous
meningococcal study has shown that the levels of PTX3 peak
already during the first hours after admission [24]. In a bacteremia
study, PTX3 levels were high in the acute phase and normalized
on recovery [23]. In another recent study conducted at the onset of
febrile neutropenia in hematologic patients it was documented that
PTX3 reached the maximal point earlier than CRP [31]. PTX3
may thus be used as an early biomarker in sepsis patients.
It is important to note that PTX3 is not a specific marker for
bacterial infection. Elevated plasma PTX3 concentrations are seen
in various inflammatory conditions. High PTX3 levels have been
shown to correlate with unfavorable outcome in several conditions
such as cardiovascular diseases [32], lung cancer [33] and
polymyalgia rheumatica [34]. A high PTX3 concentration has
also been shown to predict the severity of disease in dengue virus
infection [35], leptospirosis [36] and epidemic nephropathy [37].
In our study PTX3 values were significantly higher in patients
over 60 years and in those with obesity (body mass index (BMI)
$30), cardiovascular diseases and continuous systemic cortisone
treatment (daily dose over 10 mg oral prednisolone) compared to
those without these risk factors. These findings are well in line with
current knowledge of the inflammatory nature of these stages.
Here was no difference in PTX3 levels in patients having solid
cancer or hematological malignancies. The cohort included only
11 neutropenic hematologic patients.
In earlier studies, the utility of PTX3 as a sepsis marker has
been compared with CRP. However, PTX3 has not previously
been compared with PCT in the case of sepsis patients, although in
many papers PCT has been shown to be a better prognostic
marker than CRP [9,10,26]. In the present study, both PTX3 and
high PCT seemed to be independent predictors of severe sepsis
while CRP did not.
Several studies have shown the usefulness of PTX3 and CRP in
assessing the severity of infection [21,22,23,24,38]. In one previous
work high PTX3 has been shown to predict culture positive
bloodstream infections and severe disease (the need for ICU
treatment, longer hospital stay and acute congestive heart failure) in
Figure 1. Receiver operating characteristic (ROC) curve for plasma levels of pentraxin 3 (PTX3), procalcitonin (PCT), interleukin-6
(IL-6) and C-reactive protein (CRP) detected on admission in relation to severe sepsis and case fatality (d28) in patients with
suspected infection. AUC (ROC) (95% confidence interval, p,0.001.
doi:10.1371/journal.pone.0053661.g001
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Table 4. Clinical characteristics of patients stratified by pentraxin3 (PTX3) value detected on admission.
Clinical parameter
High PTX3, ($14.1 ng/ml)
(14.1 ng/ml), N = 130
Low PTX3 (,14.1 ng/ml)
(,14.1 ng/ml), N = 407 OR (95% Cl) p-value
Grouping variables (d 0–28) N N (%) N (%)
Case fatality (d 28) 33 17 (13.1) 16 (3.9) 3.68 (1.80–7.51) ,0.001
Case fatality (d 90) 58 24 (18.5) 34 (8.4) 2.48 (1.41–4.37) 0.002
Case fatality (12 months) 112 37 (28.5) 75 (18.4) 1.76 (1.12–2.78) 0.015
Needed ICUa stay 42 21 (16.2) 21 (5.2) 3.54 (1.87–6.729 ,0.001
Hypotensionb 28 17 (13.1) 11 (2.7) 5.42 (2.47–11.89) ,0.001
Needed vasopressors 19 10 (7.7) 9 (2.2) 3.69 (1.46–9.28) 0.006
Acute renal insufficiencyc 16 13 (10.0) 3 (0.7) 15.0 (4.19–53.40) ,0.001
DICd 8 7 (5.4) 1 (0.3) 28.08 (2.82–189.22) 0.004
Decreased GCSe 26 15 (11.5) 11 (2.7) 4.67 (2.10–10.5) ,0.001
Needed mechanical ventilationf 14 7 (5.4) 7 (1.7) 3.25 (1.12–9.45) 0.030
Needed C-PAP/bi-PAP 22 9 (6.9) 13 (3.2) 2.25 (0.94–5.40) 0.068
Severe sepsis 49 31 (23.9) 18 (4.4) 6.77 (3.64–12.59) ,0.001
MOFg 10 7 (5.4) 3 (0.7) 7.66 (1.95–30.05) 0.004
Continuous variables on admission median (quartiles) median (quartiles)
Plasma C-reactive protein (mg/l) 537 147 (39–241) 101 (35–164) 0.001
Plasma procalcitonine (ng/ml) 537 1.19 (0.31–5.63) 0.11 (0.4–0.32) ,0.001
White cell count (109/l) 523 12.7 (9.3–17.4) 10.0 (7.5–13.1) ,0.001
Platelet count (109/l) 523 221 (164–281) 264 (210–346) ,0.001
Hemoglobin 523 129 (112–143) 129 (117–143) 0.567
Plasma creatinine (mmol/l) 487 93 (64–131) 79 (64–102) 0.11
Statistical differences between groups were tested by using Pearson Chi square (category) and Mann Whitney U test (continuous variables). Odds Ratio and
95% confidence limits with logistic regression analysis. The optimal cut-off level for PTX3 for severe sepsis was counted using ROC curve analysis and Youden’s
index.
aintensive care unit.
bsystolic blood pressure ,90 mmHg or a reduction of 40 mmHg from baseline. No response to 500 ml intravenous fluid replacement.
cdiuresis ,30 ml/h at least 1 hour or continuous haemofiltration or acute dialysis treatment.
ddisseminated intravascular coagulation.
edecreased Glasgow coma scale.
fneeded mechanical ventilation otherwise than for surgery.
gMulti organ failure.
doi:10.1371/journal.pone.0053661.t004
Table 5. Multivariate logistic regression analysis evaluating the independent predictive value of pentraxin 3 (PTX3), procalcitonin
(PCT) and C-reactive protein (CRP) for severe sepsis.
Character Odds ratio 95% Confidence limits p
A. Parameters were included together in the logistic model without confounders (N = 537)
PTX3$14.1 ng/ml 3.36 1.70–6.67 ,0.001
PCT $0.30 ng/ml 5.24 2.25–12.22 ,0.001
CRP$158 mg/l 0.94 0.49–1.82 0.851
B. Parameters were taken for analysis together with statistically significant confounders (N = 537)
PTX3$14.1 ng/ml 3.02 1.50–6.01 0.002
PCT $0.30 ng/ml 5.55 2.37–13.00 ,0.001
CRP$158 mg/l 1.11 0.56–2.20 0.775
Alcohol abusea 4.88 1.69–14.09 0.003
Continuous cortisone treatmentb 4.20 1.82–9.70 ,0.001
aalcoholism was diagnosed or patient had previously been treated for alcohol-induced disease.
bcontinuous systemic cortisone treatment (daily dose more than 10 mg of oral prednisolone.
The optimal cut-offs for these parameters were counted using ROC curve analysis and Youden`s index.
doi:10.1371/journal.pone.0053661.t005
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febrile patients admitted to emergencydepartments [20]. In critically
ill ICU-patients the levelsofPTX3havecorrelatedwith theseverityof
disease and infection [21,22]. High PTX3 has been found to be an
early indicator of shock in severe meningococcal diseases [24]. The
present findingsconfirmprevious results onPTX3indetecting severe
disease, and show that PTX3 can be used in patients with suspected
infection on admission. PTX3maybeused to predictmany variables
indicating severe sepsis, i.e. need for ICU stay, hypotension, acute
renal insufficiencyandneedformechanicalventilation,already in the
emergencyroomsetting.Thus,PTX3mayhelp in stratifyingpatients
to target resources effectively.
High PTX3 and PCT levels were shown here to be independent
predictors of case fatality on day 28 when plasma samples were
taken on admission together with blood cultures from patients with
suspected infection. In one earlier study the maximum PTX3
value on days 1–4 after bacteremia diagnosis was shown to be a
predictor of case fatality (d28) [23]. Another recent study has
shown that high levels of plasma PTX3 persisting over the first five
days after onset of severe sepsis and septic shock are associated
with mortality, but in contrast to the present findings, not the
PTX3 value on day 1 [22].
In our study only a weak negative correlation between PTX3
levels and platelet count was documented. Previously it has been
shown that PTX3 can up-regulate tissue factor in activated
monocytes - a link between inflammation and clotting activity
[39]. This has also been shown in previous sepsis studies [22,24],
and PTX3 may be involved in the pathological coagulation
process in these conditions. High PTX3 level may also reflect the
role of pentraxins in the clearance of apoptotic cells [40]. Early
elevated PTX3 levels are associated with more severe forms of
sepsis, number of organ failures and poor outcome [22,41].
Some limitations must be conceded here. There were some
confounding factors in our study. Our study was designed to test
indicators of severe sepsis and case fatality in an emergency room
setting in an unselected patient population with suspected
infection. A clinician had made the decision to take blood cultures
from all patients in the emergency room and plasma samples were
taken simultaneously. We carefully sought to control for
confounding factors and would consider our results to reflect the
real life situation in an emergency room setting [26]. We could not
control the individual time delay of patients from the onset of
symptoms to hospital admission. Only one sample was studied.
The study was not designed to study the effects of antimicrobial
therapy on PTX3 levels. Study sample was taken before antibiotic
therapy in hospital but about quarter of patients had some
antimicrobial treatment before admission to hospital.
In our protocol patients were enrolled only from Sundays to
Wednesdays, but comparing this study population to a prior
evaluation made in 1551 consecutive patients before the study
commenced, no difference was seen in age, gender and the rate of
positive blood cultures or case fatality rate on day 28 between the
study and the target population. Also in the severe sepsis group the
mortality rate and distribution of infection foci were in concord
with the findings in a Finnish multicentre sepsis study [42].
The optimal PTX3 cut-off point for severe sepsis here was about
the same as one would expect from earlier studies but the optimal
cut-off for day 28 case fatality was surprisingly low, giving too low
specificity for clinical work. The results here show that PTX3
possesses statistically significant capacity as a prognostic marker
also in the emergency room setting but for better specificity the
cut-off level should be higher.
Conclusions
We showed here that high levels of PTX3 in plasma as well as
high levels of PCT can be used as prognostic markers in patients
with suspected infection admitted to the emergency room. High
PTX3 and PCT were independent predictors for severe sepsis
between day 0 and 28 and case fatality on day 28 after admission.
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Table 6. Multivariate logistic regression analysis evaluating the independent predictive value of pentraxin 3 (PTX3) and
procalcitonin (PCT) for 28-d case fatality.
Character Odds ratio 95% Confidence limits p
A. Parameters were included together in the logistic model without confounders (N = 537)
PTX3$7.7 ng/ml 2.55 1.13–5.74 0.024
PCT $0.19 ng/ml 3.54 1.36–9.18 0.009
B. Parameters were taken for analysis together with statistically significant confounders (N = 537)
PTX3$7.7 ng/ml 2.37 1.04–5.38 0.040
PCT $0.19 ng/ml 3.51 1.35–9.15 0.010
Age .60 years 3.02 1.11–8.19 0.030
Alcohol abusea 6.01 1.60–22.67 0.008
Diabetes (type 1 and 2) 2.13 0.89–5.05 0.088
Continuous cortisone treatmentb 2.28 0.93–5.59 0.073
aalcoholism was diagnosed or patient had been treated for alcohol-induced disease previously.
bcontinuous systemic cortisone treatment (daily dose more than 10 mg of oral prednisolone).
The optimal cut-offs for parameters were estimated using ROC curve analysis and Youden`s index.
doi:10.1371/journal.pone.0053661.t006
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